Study drug Lu AG13909 for congenital adrenal hyperplasia
Part of Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This early study tests Lu AG13909 in people with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. It aims to see how the drug affects hormone levels and whether it is safe for different CAH hormone patterns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed CAH type caused by 21-hydroxylase deficiency (often shown by a gene test or high 17-OHP blood level).
- Before taking your usual morning steroid dose, your 17-OHP blood level is more than 4 times the lab’s normal upper limit.
- Your body weight fits the study range: BMI between 18.5 and 40 (and at least 50 kg).
- You have been on a stable steroid (glucocorticoid) treatment for at least 1 month before screening; if you have the salt-wasting type, your mineralocorticoid is stable for at least 3 months (or at least 1 month for Part C).
- You are not pregnant and not breastfeeding.
- You haven’t had a known allergy or bad reaction to Lu AG13909.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication for children with classic congenital adrenal hyperplasia (CAH). It aims to see if the drug helps better control hormone levels and reduce the need for high doses of current steroid medicines.
This trial tests a new medicine (NBIP-01435) to see if it helps adults with classic congenital adrenal hyperplasia better manage their condition. The goal is to improve hormone levels and potentially allow for lower steroid doses.
This study tests a new drug, atumelnant, for adults with classic congenital adrenal hyperplasia (CAH) caused by 21-OHD. It aims to see if it can help control hormone levels while allowing lower doses of current steroid medications.
This trial is creating a registry to track adult males with congenital adrenal hyperplasia (CAH) from 21-hydroxylase deficiency. It helps doctors learn more about the condition and how it changes over time.
This study tests a new medicine called crinecerfont in children under 4 years old with classic congenital adrenal hyperplasia (CAH), a condition where the body doesn't make certain hormones properly. Researchers want to learn if the medicine is safe and how it works in the body.
This study aims to improve the transition from pediatric to adult care for young people with congenital adrenal hyperplasia (CAH). It will test a special transition program and may help make the shift to adult care smoother and more supported.
Hear when a new Congenital Adrenal Hyperplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.